From the Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center.
Division of Plastic and Reconstructive Surgery, Stanford University Medical Center.
Plast Reconstr Surg. 2023 Sep 1;152(3):476e-487e. doi: 10.1097/PRS.0000000000010329. Epub 2023 Feb 28.
Commercial payer-negotiated rates for cleft lip and palate surgery have not been evaluated on a national scale. The aim of this study was to characterize commercial rates for cleft care, both in terms of nationwide variation and in relation to Medicaid rates.
A cross-sectional analysis was performed of 2021 hospital pricing data from Turquoise Health, a data service platform that aggregates hospital price disclosures. The data were queried by CPT code to identify 20 cleft surgical services. Within- and across-hospital ratios were calculated per CPT code to quantify commercial rate variation. Generalized linear models were used to assess the relationship between median commercial rate and facility-level variables and between commercial and Medicaid rates.
There were 80,710 unique commercial rates from 792 hospitals. Within-hospital ratios for commercial rates ranged from 2.0 to 2.9 and across-hospital ratios ranged from 5.4 to 13.7. Median commercial rates per facility were higher than Medicaid rates for primary cleft lip and palate repair ($5492.20 versus $1739.00), secondary cleft lip and palate repair ($5429.10 versus $1917.00), and cleft rhinoplasty ($6001.00 versus $1917.00; P < 0.001). Lower commercial rates were associated with hospitals that were smaller ( P < 0.001), safety-net ( P < 0.001), and nonprofit ( P < 0.001). Medicaid rate was positively associated with commercial rate ( P < 0.001).
Commercial rates for cleft surgical care demonstrated marked variation within and across hospitals, and were lower for small, safety-net, or nonprofit hospitals. Lower Medicaid rates were not associated with higher commercial rates, suggesting that hospitals did not use cost-shifting to compensate for budget shortfalls resulting from poor Medicaid reimbursement.
商业支付方协商的唇腭裂手术价格尚未在全国范围内进行评估。本研究旨在从全国范围内的差异以及与医疗补助(Medicaid)费率的关系两方面,对腭裂护理的商业费率进行特征描述。
通过 Turquoise Health 这一数据服务平台,对 2021 年的医院定价数据进行了横断面分析。该平台汇总了医院价格披露信息,通过 CPT 代码查询了 20 项腭裂手术服务。针对每个 CPT 代码计算了医院内和医院间的比率,以量化商业费率的变化。使用广义线性模型评估了中位数商业费率与医疗机构水平变量之间的关系,以及商业费率与医疗补助费率之间的关系。
从 792 家医院获得了 80710 个独特的商业费率。商业费率的医院内比率范围为 2.0 至 2.9,医院间比率范围为 5.4 至 13.7。每个医疗机构的中位数商业费率均高于医疗补助的唇腭裂初次修复术(5492.20 美元比 1739.00 美元)、唇腭裂二次修复术(5429.10 美元比 1917.00 美元)和腭裂整复术(6001.00 美元比 1917.00 美元;P < 0.001)。商业费率较低与规模较小(P < 0.001)、面向医疗救助人群(P < 0.001)和非营利性(P < 0.001)的医院相关。医疗补助费率与商业费率呈正相关(P < 0.001)。
腭裂手术护理的商业费率在医院内和医院间差异显著,且规模较小、面向医疗救助人群或非营利性的医院的商业费率较低。较低的医疗补助费率与较高的商业费率无关,这表明医院并未通过成本转移来弥补因医疗补助报销不足而导致的预算短缺。